Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486208 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT05486208 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 102 participants.
The verdict
NCT05486208, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 88, 116, and 186 days with 10, 13, and 14 visits for each participant in parts A, B, and C, respectively.
Interventions
- DRUG Placebo
- DRUG LY3844583
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2024-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05486208
The ClinicalTrials.gov registry entry for NCT05486208 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05486208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05486208 about?
NCT05486208 is a clinical study titled "A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis". The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy p...
What is the current status of trial NCT05486208?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2022-08-11. Estimated completion is 2024-01-20.
What interventions are being tested in trial NCT05486208?
The interventions under investigation include: Placebo (DRUG), LY3844583 (DRUG).
Who is sponsoring clinical trial NCT05486208?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.